GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Virax Biolabs Group Ltd (NAS:VRAX) » Definitions » Inventories, Finished Goods

Virax Biolabs Group (Virax Biolabs Group) Inventories, Finished Goods : $0.03 Mil (As of Sep. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Virax Biolabs Group Inventories, Finished Goods?

Virax Biolabs Group's quarterly finished goods stayed the same from Sep. 2022 ($0.00 Mil) to Mar. 2023 ($0.00 Mil) but then increased from Mar. 2023 ($0.00 Mil) to Sep. 2023 ($0.03 Mil).

Virax Biolabs Group's annual finished goods stayed the same from Mar. 2021 ($0.02 Mil) to Mar. 2022 ($0.02 Mil) but then declined from Mar. 2022 ($0.02 Mil) to Mar. 2023 ($0.00 Mil).


Virax Biolabs Group Inventories, Finished Goods Historical Data

The historical data trend for Virax Biolabs Group's Inventories, Finished Goods can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Virax Biolabs Group Inventories, Finished Goods Chart

Virax Biolabs Group Annual Data
Trend Mar20 Mar21 Mar22 Mar23
Inventories, Finished Goods
- 0.02 0.02 -

Virax Biolabs Group Semi-Annual Data
Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23
Inventories, Finished Goods Get a 7-Day Free Trial 0.02 0.02 - - 0.03

Virax Biolabs Group Inventories, Finished Goods Calculation

The products in a manufacturer's inventory that are completed and are waiting to be sold.


Virax Biolabs Group (Virax Biolabs Group) Business Description

Traded in Other Exchanges
N/A
Address
20 North Audley Street, London, GBR, W1K 6LX
Virax Biolabs Group Ltd is a innovative biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against major global viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus.